Latest News
Zeta Global Extends AI-Led Rally in Premarket Trading
Zeta Global shares climbed 5.42% in premarket trading Monday, building on a 13.43% Friday surge driven by strong Q1 earnings and AI momentum.
Nu Holdings Starts June Flat Amid Colombia Expansion and Rising Credit Costs
Nu Holdings (NU) opened June flat at $13.13, with a 3.14% five-day gain but a 21.57% year-to-date drop. The company's $130M Colombia expansion and rising credit costs are in focus.
United Rentals Approaches $1,000 as Institutions Boost Stakes
United Rentals trades near $1,000 after institutional filings reveal increased stakes. Q1 rental revenue rose 8.7% to $3.42B; 2026 guidance raised.
CoreWeave Shares Surge Premarket on Index Inclusion and AI Deal
CoreWeave shares surged 5.65% premarket after a preliminary Russell 3000 index addition and a $20 million AI-inference funding round backed by CoreWeave.
Full Truck Alliance Shares Hover Near Flat After Cederberg Capital Exits Stake
Full Truck Alliance (YMM) shares barely moved premarket after Cederberg Capital exited its $20 million stake. Q1 results revealed order growth of 14.3% but a drop in net income and rising non-performing loans.
Super Micro Gains on New Nvidia AI Blueprints, Analyst Price Target Hike
Super Micro Computer shares edged higher after unveiling Nvidia Vera Rubin-based data center designs and receiving a price target increase from Mizuho, though an ongoing board review over export-control matters keeps some investors cautious.
Snap Stock Steady at $5.71 as Ad Recovery Hopes Tested
Snap stock stayed at $5.71 after a 3.4% Friday decline, with Q1 revenue rising 12% to $1.529 billion but ad revenue growth slowing to 3%. Investors assess user gains against North America weakness and stiff competition.
Nokia Surges on AI Demand and Insider Share Purchase
Nokia stock surged 5.39% to 13.16 euros, driven by AI demand and a $706,500 insider purchase. Shares are up over 130% in 2026.
Revolution Medicines Stock Gains Pre-Market on Promising Pancreatic Cancer Data
Revolution Medicines shares gained 1.9% premarket after Phase 3 data showed its experimental pill daraxonrasib nearly doubled median survival in pancreatic cancer to 13.2 months versus 6.7 months for chemotherapy.